DGAP-Ad hoc: MOLOGEN AG

Insider information according to article 17 MAR

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

MOLOGEN AG: US investor signs Share Subscription Facility

Berlin, 24 October 2017 - The Executive Board of biopharmaceutical company MOLOGEN AG (ISIN DE0006637200, SIN 663720) today signed, with the approval of the Supervisory Board, a "Share Subscription Facility" with the US investor Global Corporate Finance (GCF). According to this agreement GCF commits to purchase up to 3,394,725 shares in MOLOGEN AG to be issued in several tranches from MOLOGEN's authorized share capital pursuant to section 4(3) of the articles of association. The capital increases will be executed without subscription rights of existing shareholders.

Under the terms of the agreement, MOLOGEN has the right (but is under no obligation) to issue, in its sole discretion, several so-called "Draw Down Notices" in an amount of up to EUR 1,000,000 each (depending on certain circumstances) for a period of 30 months. For each amount drawn down at MOLOGEN's request, GCF shall purchase new MOLOGEN shares at a price equal to 95% of the five consecutive trading days Volume Weighted Average Price (VWAP) following the relevant Draw Down Notice. Under the Share Purchase Facility, MOLOGEN is completely free to conduct additional or other financing measures. Currently, MOLOGEN envisages to fully exercise its draw down rights under the Share Purchase Facility and issue in total 3,394,725 new shares over the upcoming months.

A German financial institution acting as intermediary will deliver the respective shares to GCF on short notice. This delivery will be bridged through a permanent share loan from the main shareholder of MOLOGEN AG, until the new shares are issued and admitted to trading on the regulated market of the Frankfurt Stock Exchange in Germany. Therefore, this shareholder may be obligated release respective voting rights notifications in case the voting rights would exceed or fall below certain thresholds.

Based on current share prices and subject to the exercise of all tranches, MOLOGEN could raise total gross proceeds of around EUR 10 million which would be used to finance the Company's operations and, in particular, for the further implementation of the strategy "Next level" beyond Q1 2018.

GCF is a private US Family Office with a focus on micro and mid cap companies in emerging markets, providing a global footprint for proprietary partnering resources, expertise, and funding. GCF outlined that they are focused on a long-term investment in MOLOGEN. Thus, if MOLOGEN draws down the tranches under the Share Subscription Facility, GCF could become a new main shareholder of MOLOGEN.

Important note:
This announcement is not an offer of securities for sale in the United States, Australia, Canada, Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this press release have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offering of the securities in the United States of America. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan.

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.